This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an anticoccidial in
poultry, or to vary the conditions on a registered anticoccidial in poultry. It also
incorporates guidelines, which are intended to provide more detailed information and
guidance to applicants to assist them in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an antihistamine
product, or to vary the conditions on a registered antihistamine product. It also
incorporates guidelines, which are intended to provide more detailed information and
guidance to applicants to assist them in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an antispasmodic
product, or to vary the conditions on a registered antispasmodic product. It also
incorporates guidelines, which are intended to provide more detailed information and
guidance to applicants to assist them in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register a corticosteroid or
to vary the conditions on a registered corticosteroid. It also incorporates guidelines,
which are intended to provide more detailed information and guidance to applicants to
assist them in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register an emetic, or to
vary the conditions on a registered emetic. It also incorporates guidelines, which are
intended to provide more detailed information and guidance to applicants to assist them
in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register a vaccine, or to
vary the conditions on a registered vaccine. It also incorporates guidelines, which are
intended to provide more detailed information and guidance to applicants to assist them
in complying with the standard.

This document specifies the minimum study and reporting requirements, i.e. the standard,
for efficacy studies submitted in support of an application to register a zinc prophylactic
product for facial eczema, or to vary the conditions on a registered zinc prophylactic
product for facial eczema. It also incorporates guidelines, which are intended to provide
more detailed information and guidance to applicants to assist them in complying with
the standard.

The adverse event reporting programme is part of the quality assurance programme developed by the Ministry for Primary Industries (MPI). It aims to ensure that all agricultural chemicals in the marketplace are efficacious, of acceptable quality, used appropriately, and that product labels provide sufficient consumer information for correct use.

Explains the Adverse Event Reporting Programme and actions to take if an adverse event with an agricultural chemical occurs.

This is a quality assurance programme developed by the Ministry for Primary Industries (MPI). It aims to ensure that all veterinary medicines in the marketplace are safe, efficacious, of acceptable quality, used appropriately, and that product labels provide sufficient consumer information for correct use.

This document specifies the minimum study and reporting requirements for efficacy and host safety studies submitted in support of an application to register an antimicrobial agent preparation to be applied post- milking to disinfect teats, referred to in future as a teat disinfectant. The requirements also apply to applications to vary the conditions on a registered teat disinfectant.

This guidance document is to provide information on the process of becoming an MPI-listed data assessor to carry out independent data assessment in specified areas and to prepare data assessment reports concerning trade name products for registration (or variation) applications under the ACVM Act.

This organism causes the most commonly reported gastrointestinal disease in New Zealand. The two species Campylobacter jejuni and C. coli are most often associated with disease. It grows best in reduced oxygen atmospheres and only at temperatures
exceeding room temperature.